Expand CMPS Menu
CMPS MENU

CMPS Latest Press Releases

-- February 18, 2026 --

Compass Pathways Announces Pricing of $150 Million Public Offering Business Wire 8:18 PM

-- February 17, 2026 --

Compass Pathways Launches Proposed $150.0 Million Public Offering Business Wire 4:06 PM
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Business Wire 6:30 AM

-- February 16, 2026 --

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials Business Wire 8:00 AM

-- January 7, 2026 --

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD Business Wire 6:30 AM

-- January 6, 2026 --

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360 Business Wire 6:30 AM

-- December 9, 2025 --

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET Business Wire 6:30 AM

-- November 20, 2025 --

Compass Pathways to Participate in Two Investor Conferences in December Business Wire 6:30 AM

-- November 5, 2025 --

Compass Pathways to Participate in Stifel 2025 Healthcare Conference Business Wire 6:30 AM

-- November 4, 2025 --

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months Business Wire 6:30 AM

-- October 30, 2025 --

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression PRNewswire 8:30 AM

-- October 29, 2025 --

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors Business Wire 6:30 AM

-- October 28, 2025 --

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025 Business Wire 6:30 AM
Market Data Delayed 15 Minutes